Bayer AG
XETRA:BAYN
Intrinsic Value
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. [ Read More ]
The intrinsic value of one BAYN stock under the Base Case scenario is 116.8 EUR. Compared to the current market price of 25.855 EUR, Bayer AG is Undervalued by 78%.
Valuation Backtest
Bayer AG
Run backtest to discover the historical profit from buying and selling BAYN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bayer AG
Current Assets | 37.6B |
Cash & Short-Term Investments | 10.7B |
Receivables | 12.8B |
Other Current Assets | 14B |
Non-Current Assets | 78.7B |
Long-Term Investments | 3.1B |
PP&E | 13.3B |
Intangibles | 55.7B |
Other Non-Current Assets | 6.6B |
Current Liabilities | 29.5B |
Accounts Payable | 7.5B |
Other Current Liabilities | 22B |
Non-Current Liabilities | 53.9B |
Long-Term Debt | 38.2B |
Other Non-Current Liabilities | 15.7B |
Earnings Waterfall
Bayer AG
Revenue
|
47.6B
EUR
|
Cost of Revenue
|
-19.7B
EUR
|
Gross Profit
|
27.9B
EUR
|
Operating Expenses
|
-19.5B
EUR
|
Operating Income
|
8.4B
EUR
|
Other Expenses
|
-11.4B
EUR
|
Net Income
|
-2.9B
EUR
|
Free Cash Flow Analysis
Bayer AG
What is Free Cash Flow?
BAYN Profitability Score
Profitability Due Diligence
Bayer AG's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Bayer AG's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
BAYN Solvency Score
Solvency Due Diligence
Bayer AG's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Bayer AG's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BAYN Price Targets Summary
Bayer AG
According to Wall Street analysts, the average 1-year price target for BAYN is 35.56 EUR with a low forecast of 25.25 EUR and a high forecast of 64.05 EUR.
Shareholder Return
BAYN Price
Bayer AG
Average Annual Return | 0.51% |
Standard Deviation of Annual Returns | 22.58% |
Max Drawdown | -61% |
Market Capitalization | 25.4B EUR |
Shares Outstanding | 982 424 100 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 99,637 full-time employees. The firm's segments are Pharmaceuticals, Consumer Health, Crop Science. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The firm is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds.
Contact
IPO
Employees
Officers
The intrinsic value of one BAYN stock under the Base Case scenario is 116.8 EUR.
Compared to the current market price of 25.855 EUR, Bayer AG is Undervalued by 78%.